94 related articles for article (PubMed ID: 30245169)
1. Using a surgical prostate-specific antigen threshold of >0.2 ng/mL to define biochemical failure for intermediate- and high-risk prostate cancer patients treated with definitive radiation therapy in the ASCENDE-RT randomized control trial.
Morris WJ; Pickles T; Keyes M
Brachytherapy; 2018; 17(6):837-844. PubMed ID: 30245169
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen nadir within 12 months as an early surrogate marker of biochemical failure and distant metastasis after low-dose-rate brachytherapy or external beam radiotherapy for localized prostate cancer.
Nishimura S; Ohashi T; Momma T; Sakayori M; Eriguchi T; Tanaka T; Yamashita S; Kosaka T; Oya M; Shigematsu N
Cancer Med; 2018 May; 7(5):1794-1801. PubMed ID: 29577651
[TBL] [Abstract][Full Text] [Related]
3. Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate-risk prostate cancer: long-term results of CALGB 99809.
Hurwitz MD; Halabi S; Archer L; McGinnis LS; Kuettel MR; DiBiase SJ; Small EJ
Cancer; 2011 Dec; 117(24):5579-88. PubMed ID: 22535500
[TBL] [Abstract][Full Text] [Related]
4. Reirradiation salvage radiotherapy for recurrent prostate cancer after primary low-dose brachytherapy.
Muñoz Muñoz Ó; Gomis Sellés E; Delgado León BD; Mateos Perez JC; Baeza Trujillo M; Perucha Ortega M; López Guerra JL; Cabrera Roldán P
Clin Transl Oncol; 2024 Apr; 26(4):872-879. PubMed ID: 37672205
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Quality-of-Life Outcomes After Prostate Radiation Therapy With or Without High-Dose-Rate Brachytherapy Boost: Post Hoc Analysis of TROG 03.04 RADAR.
Ong WL; Nikitas J; Joseph D; Steigler A; Millar J; Valle L; Steinberg ML; Ma TM; Reiter RE; Rettig MB; Nickols NG; Chang A; Zaorsky NG; Spratt DE; Romero T; Kishan AU
Int J Radiat Oncol Biol Phys; 2024 Jul; 119(3):813-825. PubMed ID: 37802226
[TBL] [Abstract][Full Text] [Related]
6. The biochemical recurrence-free rate in patients who underwent prostate low-dose-rate brachytherapy, using two different definitions.
Tanaka N; Asakawa I; Katayama E; Hirayama A; Hasegawa M; Konishi N; Fujimoto K
Radiat Oncol; 2014 May; 9():107. PubMed ID: 24885896
[TBL] [Abstract][Full Text] [Related]
7. A Randomized Trial Comparing Quality of Life After Low-Dose Rate or High-Dose Rate Prostate Brachytherapy Boost With Pelvic External Beam Radiation Therapy.
Crook J; Moideen N; Arbour G; Castro F; Araujo C; Batchelar D; Halperin R; Hilts M; Kim D; Petrik D; Rose J; Cheng JC; Bachand F
Int J Radiat Oncol Biol Phys; 2024 Mar; ():. PubMed ID: 38493901
[TBL] [Abstract][Full Text] [Related]
8. Five-year effectiveness of low-dose-rate brachytherapy: comparisons with nomogram predictions in patients with non-metastatic prostate cancer presenting significant control of intra- and periprostatic disease.
Zimmermann JS; Osieka R; Bruns T; Hollberg H; Wiechmann B; Netzbandt O; Sablotny J; Malade M; Heitz M; Bernhardt F; Tiemann J; Wilkens M; Brüske T; Welker U; Heinemann V; Zimmermann P; de la Maza SF; Pfeiffer D; Tauber PR; Thomas D; Moustakis C
J Contemp Brachytherapy; 2018 Aug; 10(4):297-305. PubMed ID: 30237813
[TBL] [Abstract][Full Text] [Related]
9. Comparison of EBRT and I-125 seed brachytherapy concerning outcome in intermediate-risk prostate cancer.
Moll M; Renner A; Kirisits C; Paschen C; Zaharie A; Goldner G
Strahlenther Onkol; 2021 Nov; 197(11):986-992. PubMed ID: 34351453
[TBL] [Abstract][Full Text] [Related]
10. Treatment intensification strategies for men undergoing definitive radiotherapy for high-risk prostate cancer.
Nikitas J; Kishan A; Chang A; Duriseti S; Nichols NG; Reiter R; Rettig M; Brisbane W; Steinberg ML; Valle L
World J Urol; 2024 Mar; 42(1):165. PubMed ID: 38492111
[TBL] [Abstract][Full Text] [Related]
11. Biochemical control in intermediate- and high-risk prostate cancer after EBRT with and without brachytherapy boost.
Moll M; Magrowski Ł; Mittlböck M; Heinzl H; Kirisits C; Ciepał J; Masri O; Heilemann G; Stando R; Krzysztofiak T; Depowska G; d'Amico A; Techmański T; Kozub A; Majewski W; Suwiński R; Wojcieszek P; Sadowski J; Widder J; Goldner G; Miszczyk M
Strahlenther Onkol; 2024 Jun; ():. PubMed ID: 38829436
[TBL] [Abstract][Full Text] [Related]
12. Salvage radiotherapy after high-intensity focused ultrasound treatment for localized prostate cancer: feasibility, tolerance and efficacy.
Ripert T; Bayoud Y; Messaoudi R; Ménard J; Azémar MD; Duval F; Nguyen TD; Staerman F
Can Urol Assoc J; 2012 Oct; 6(5):E179-83. PubMed ID: 21539766
[TBL] [Abstract][Full Text] [Related]
13. Low-dose-rate brachytherapy and long-term treatment outcomes in patients younger than 60 years of age.
Armstrong A; Ho H; Mark Tacey M; Bolton D; Chan Y; Tan A; Cham CW; Pham T; McMillan K; Koufogiannis G; Dip G; Manohar P; Guerrieri M; Ng M; Joon DL; Foroudi F; Tan MY; Chao M
J Contemp Brachytherapy; 2024 Feb; 16(1):6-11. PubMed ID: 38584883
[TBL] [Abstract][Full Text] [Related]
14. Clinical Efficacy and Openness to New Challenges of Low Dose Rate Brachytherapy for Prostate Cancer.
Kato M; Higashi S; Sugino Y; Kajiwara S; Tanaka S; Kitano G; Yamashita Y; Ogura Y; Tachibana H; Kojima T; Inoue T
Curr Oncol; 2023 Nov; 30(11):9824-9835. PubMed ID: 37999133
[TBL] [Abstract][Full Text] [Related]
15. Canadian prostate brachytherapy in 2012.
Keyes M; Crook J; Morris WJ; Morton G; Pickles T; Usmani N; Vigneault E
Can Urol Assoc J; 2013; 7(1-2):51-8. PubMed ID: 23671495
[TBL] [Abstract][Full Text] [Related]
16. Quantitative mathematical modeling of PSA dynamics of prostate cancer patients treated with intermittent androgen suppression.
Hirata Y; Akakura K; Higano CS; Bruchovsky N; Aihara K
J Mol Cell Biol; 2012 Jun; 4(3):127-32. PubMed ID: 22561841
[TBL] [Abstract][Full Text] [Related]
17. Lonidamine Induced Selective Acidification and De-Energization of Prostate Cancer Xenografts: Enhanced Tumor Response to Radiation Therapy.
Orlovskiy S; Gupta PK; Roman J; Arias-Mendoza F; Nelson DS; Koch CJ; Narayan V; Putt ME; Nath K
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38611062
[TBL] [Abstract][Full Text] [Related]
18. Characterising potential bone scan overuse amongst men treated with radical prostatectomy.
Kirk PS; Borza T; Caram MEV; Shumway DA; Makarov DV; Burns JA; Shelton JB; Leppert JT; Chapman C; Chang M; Hollenbeck BK; Skolarus TA
BJU Int; 2019 Jul; 124(1):55-61. PubMed ID: 30246937
[TBL] [Abstract][Full Text] [Related]
19. Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer.
Tosco L; Briganti A; D'amico AV; Eastham J; Eisenberger M; Gleave M; Haustermans K; Logothetis CJ; Saad F; Sweeney C; Taplin ME; Fizazi K
Eur Urol; 2019 Jan; 75(1):44-60. PubMed ID: 30286948
[TBL] [Abstract][Full Text] [Related]
20. Primary Whole-gland Cryoablation for Prostate Cancer: Biochemical Failure and Clinical Recurrence at 5.6 Years of Follow-up.
Oishi M; Gill IS; Ashrafi AN; Lin-Brande M; Nassiri N; Shin T; Bove A; Cacciamani GE; Ukimura O; Bahn DK; Abreu ALC
Eur Urol; 2019 Feb; 75(2):208-214. PubMed ID: 30274702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
